Condition: Small Cell Lung Cancer · Sponsor: Daiichi Sankyo
This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
This description comes directly from the study's public registry record.
Daiichi Sankyo Contact for Clinical Trial Information · 9089926400 · CTRinfo@dsi.com
Always discuss trial participation with your own doctor first.
| Highlands Oncology Group | Springdale, Arkansas, United States | Recruiting |
| Clinical Research Providence Medical Foundation | Fullerton, California, United States | Recruiting |
| UCLA Hematology-Oncology | Los Angeles, California, United States | Recruiting |
| UCSF Mission Bay Mission Hall | San Francisco, California, United States | Recruiting |
| University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Recruiting |
| AdventHealth Orlando, Cancer Institute | Orlando, Florida, United States | Recruiting |
| H. Lee Moffitt Cancer Center and Research Institute, Inc | Tampa, Florida, United States | Not Yet Recruiting |
| Rush MD Anderson Cancer Center | Chicago, Illinois, United States | Recruiting |
| Baptist Health Lexington | Lexington, Kentucky, United States | Recruiting |
| University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
| John Hopkins School of Medicine | Baltimore, Maryland, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
+ 220 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06203210